title: Mutational analysis of flucytosine resistance in Candida glabrata.
abstract: The antifungal flucytosine (5-fluorocytosine [5FC]) is a prodrug metabolized to its toxic form, 5-fluorouracil (5FU), only by organisms expressing cytosine deaminase. One such organism is Candida glabrata, which has emerged as the second most common agent of bloodstream and mucosal candidiasis. This emergence has been attributed to the high rate at which C. glabrata develops resistance to azole antifungals. As an oral agent, 5FC represents an attractive alternative or complement to azoles; however, the frequency of 5FC resistance mutations and the mechanisms by which these mutations confer resistance have been explored only minimally. On RPMI 1640 medium containing 1 μg/ml 5FC (32-fold above the MIC, but less than 1/10 of typical serum levels), resistant mutants occurred at a relatively low frequency (2 × 10⁻⁷). Three of six mutants characterized were 5FU cross-resistant, suggesting a mutation downstream of the Fcy1 gene (cytosine deaminase), which was confirmed by sequence analysis of the Fur1 gene (uracil phosphoribosyl transferase). The remaining three mutants had Fcy1 mutations. To ascertain the effects of 5FC resistance mutations on enzyme function, mutants were isolated in ura3 strains. Three of seven mutants harbored Fcy1 mutations and failed to grow in uridine-free, cytosine-supplemented medium, consistent with inactive Fcy1. The remainder grew in this medium and had wild-type Fcy1; further analysis revealed these to be mutated in the Fcy2L homolog of S. cerevisiae Fcy2 (purine-cytosine transporter). Based on this analysis, we characterized three 5FC-resistant clinical isolates, and mutations were identified in Fur1 and Fcy1. These data provide a framework for understanding 5FC resistance in C. glabrata and potentially in other fungal pathogens.
authors.affiliation: Department of Microbiology and Immunology, Drexel University College of Medicine, 2900 Queen Lane, Philadelphia, PA 19129, USA. tedlind@drexelmed.edu
authors.forename: Thomas D
authors.initials: TD
authors.lastname: Edlind
authors.forename: Santosh K
authors.initials: SK
authors.lastname: Katiyar
mesh_terms: D000935:Antifungal Agents / Q000494:pharmacology*; D041221:Candida glabrata / Q000187:drug effects* / Q000235:genetics*; D004252:DNA Mutational Analysis; D025141:Drug Resistance, Fungal / Q000235:genetics*; D005437:Flucytosine / Q000494:pharmacology*; D005656:Fungal Proteins / Q000235:genetics / Q000502:physiology; D008826:Microbial Sensitivity Tests; D016133:Polymerase Chain Reaction
chemical_list: D000935:Antifungal Agents; D005656:Fungal Proteins; D005437:Flucytosine
references.citation: Gene. 1990 Apr 16;88(2):149-57
references.pmid: 2189783
references.citation: Clin Microbiol Rev. 2007 Jan;20(1):133-63
references.pmid: 17223626
references.citation: Mol Microbiol. 2006 Aug;61(3):704-22
references.pmid: 16803598
references.citation: J Bacteriol. 1970 Jun;102(3):607-15
references.pmid: 5429721
references.citation: Antimicrob Agents Chemother. 2010 Mar;54(3):1360-2
references.pmid: 20038613
references.citation: J Mol Biol. 2001 Jan 19;305(3):567-80
references.pmid: 11152613
references.citation: Curr Genet. 1991 May;19(5):333-7
references.pmid: 1913872
references.citation: Structure. 2003 Aug;11(8):961-72
references.pmid: 12906827
references.citation: Antimicrob Agents Chemother. 2009 Jul;53(7):2982-90
references.pmid: 19414575
references.citation: J Antimicrob Chemother. 1999 Jun;43(6):767-75
references.pmid: 10404315
references.citation: Antimicrob Agents Chemother. 2004 Jan;48(1):262-6
references.pmid: 14693548
references.citation: Crit Rev Microbiol. 1987;15(1):45-56
references.pmid: 3319420
references.citation: J Biol Chem. 2003 May 23;278(21):19111-7
references.pmid: 12637534
references.citation: Curr Genet. 1997 Jan;31(1):1-6
references.pmid: 9000374
references.citation: Yeast. 2006 Jul 15;23(9):707-15
references.pmid: 16845689
references.citation: Mol Microbiol. 1990 Apr;4(4):585-96
references.pmid: 2191181
references.citation: J Clin Microbiol. 2005 May;43(5):2155-62
references.pmid: 15872235
references.citation: Curr Med Res Opin. 2009 Jul;25(7):1732-40
references.pmid: 19519284
references.citation: Proc Natl Acad Sci U S A. 2002 Jan 8;99(1):78-83
references.pmid: 11773618
references.citation: Antimicrob Agents Chemother. 2004 Oct;48(10):3773-81
references.pmid: 15388433
references.citation: Antimicrob Agents Chemother. 2004 Nov;48(11):4377-86
references.pmid: 15504867
references.citation: Antimicrob Agents Chemother. 2009 May;53(5):1772-8
references.pmid: 19258277
references.citation: Antimicrob Agents Chemother. 2009 Nov;53(11):4678-85
references.pmid: 19704126
references.citation: J Antimicrob Chemother. 2000 Aug;46(2):171-9
references.pmid: 10933638
references.citation: Curr Genet. 2003 Apr;43(1):62-9
references.pmid: 12684846
references.citation: Antimicrob Agents Chemother. 2009 Sep;53(9):3690-9
references.pmid: 19546367
references.citation: J Dent Res. 2007 Mar;86(3):204-15
references.pmid: 17314251
references.citation: J Gen Microbiol. 1990 Aug;136(8):1475-81
references.pmid: 2262788
references.citation: Rev Iberoam Micol. 2004 Jun;21(2):63-9
references.pmid: 15538829
references.citation: Antimicrob Agents Chemother. 2002 Nov;46(11):3518-21
references.pmid: 12384359
references.citation: Mycopathologia. 2011 Jan;171(1):11-21
references.pmid: 20617462
references.citation: Antimicrob Agents Chemother. 2004 Jun;48(6):2223-7
references.pmid: 15155225
references.citation: J Clin Microbiol. 2005 May;43(5):2163-7
references.pmid: 15872236